Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "IFF"

1266 News Found

Shilpa Medicare receives USFDA approval for Bortezomib injection
Drug Approval | August 27, 2024

Shilpa Medicare receives USFDA approval for Bortezomib injection

Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)


Honeywell launches quality management system HQMR for Life Sciences industry
News | August 26, 2024

Honeywell launches quality management system HQMR for Life Sciences industry

Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance


Royal Sense launches stergic dengue IgG/IgM rapid test
Healthcare | August 25, 2024

Royal Sense launches stergic dengue IgG/IgM rapid test

The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples


Aster DM Healthcare launches Tele ICU Services in India
News | August 22, 2024

Aster DM Healthcare launches Tele ICU Services in India

The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India


EMA validates Bristol Myers Squibb’s application for CAR T cell therapy Breyanzi for relapsed or refractory follicular lymphoma
News | August 19, 2024

EMA validates Bristol Myers Squibb’s application for CAR T cell therapy Breyanzi for relapsed or refractory follicular lymphoma

Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile


Evonik expands its formulation capabilities for lipid nanoparticles
News | August 15, 2024

Evonik expands its formulation capabilities for lipid nanoparticles

Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations


Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
News | August 13, 2024

Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth

European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24


Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Drug Approval | August 13, 2024

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer

Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years


Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr
News | August 11, 2024

Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr

Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues


Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
News | August 10, 2024

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.